Passively Transferred Human NMO-IgG Exacerbates Demyelination in Mouse Experimental Autoimmune Encephalomyelitis

Overview

Journal BMC Neurol

Publisher Biomed Central

Specialty Neurology

Date 2013 Aug 10

PMID 23927715

Citations 12

Authors

Harleen Saini

Robert Rifkin

Michael Gorelik

Hwa Huang

Zachary Ferguson

Melina V Jones

Michael Levy

Affiliations

Soon will be listed here.

Abstract

Background: Neuromyelitis optica (NMO) is a devastating inflammatory disorder of the optic nerves and spinal cord characterized by frequently recurring exacerbations of humoral inflammation. NMO is associated with the highly specific NMO-IgG biomarker, an antibody that binds the aquaporin-4 water channel. Aquaporin-4 is present on glial endfeet in the central nervous system (CNS). In humans, the NMO-IgG portends more frequent exacerbations and a worse long-term clinical outcome.

Methods: We tested the longer-term outcome of mice with EAE injected with NMO-IgG and followed them for 60 days. Clinical exams and pathology of the spinal cord and optic nerves were compared to mice that received control human IgG.

Results: Passively transferred human NMO-IgG leads to more severe neurology disability over two months after onset of disease. Clinical worsening is associated with an increased concentration of large demyelinating lesions primarily to subpial AQP4-rich regions of the spinal cord.

Conclusions: NMO-IgG is pathogenic in the context of EAE in mice.

Citing Articles

Scientific issues with rodent models of neuromyelitis optic spectrum disorders.

Huang Y, Wang T, Wang F, Wu Y, Ai J, Zhang Y Front Immunol. 2024; 15:1423107.

PMID: 39628487 PMC: 11611858. DOI: 10.3389/fimmu.2024.1423107.

IL-33 relieves nerve injury by mediating microglial polarization in neuromyelitis optica spectrum disorders via the IL-33/ST2 pathway.

Huang L, Fu C, Liao S, Long Y IBRO Neurosci Rep. 2024; 17:177-187.

PMID: 39220229 PMC: 11364135. DOI: 10.1016/j.ibneur.2024.07.008.

Modelling MOG antibody-associated disorder and neuromyelitis optica spectrum disorder in animal models: Spinal cord manifestations.

Remlinger J, Bagnoud M, Meli I, Massy M, Linington C, Chan A Mult Scler Relat Disord. 2023; 78:104892.

PMID: 37499337 PMC: 11792092. DOI: 10.1016/j.msard.2023.104892.

Modeling MOG Antibody-Associated Disorder and Neuromyelitis Optica Spectrum Disorder in Animal Models: Visual System Manifestations.

Remlinger J, Bagnoud M, Meli I, Massy M, Hoepner R, Linington C Neurol Neuroimmunol Neuroinflamm. 2023; 10(5).

PMID: 37429715 PMC: 10691219. DOI: 10.1212/NXI.0000000000200141.

Low Frequency Ultrasound With Injection of NMO-IgG and Complement Produces Lesions Different From Experimental Autoimmune Encephalomyelitis Mice.

Xiang W, Xie C, Luo J, Zhang W, Zhao X, Yang H Front Immunol. 2021; 12:727750.

PMID: 34721390 PMC: 8551829. DOI: 10.3389/fimmu.2021.727750.

References

Graber D, Levy M, Kerr D, Wade W . Neuromyelitis optica pathogenesis and aquaporin 4. J Neuroinflammation. 2008; 5:22. PMC: 2427020. DOI: 10.1186/1742-2094-5-22. View

Jones M, Nguyen T, Deboy C, Griffin J, Whartenby K, Kerr D . Behavioral and pathological outcomes in MOG 35-55 experimental autoimmune encephalomyelitis. J Neuroimmunol. 2008; 199(1-2):83-93. DOI: 10.1016/j.jneuroim.2008.05.013. View

Hinson S, McKeon A, Fryer J, Apiwattanakul M, Lennon V, Pittock S . Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. Arch Neurol. 2009; 66(9):1164-7. DOI: 10.1001/archneurol.2009.188. View

Weinstock-Guttman B, Miller C, Yeh E, Stosic M, Umhauer M, Batra N . Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica. Mult Scler. 2008; 14(8):1061-7. DOI: 10.1177/1352458508092811. View

Roemer S, Parisi J, Lennon V, Benarroch E, Lassmann H, Bruck W . Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain. 2007; 130(Pt 5):1194-205. DOI: 10.1093/brain/awl371. View

Kinoshita M, Nakatsuji Y, Kimura T, Moriya M, Takata K, Okuno T . Neuromyelitis optica: Passive transfer to rats by human immunoglobulin. Biochem Biophys Res Commun. 2009; 386(4):623-7. DOI: 10.1016/j.bbrc.2009.06.085. View

Frohman E, Kerr D . Is neuromyelitis optica distinct from multiple sclerosis?: something for "lumpers" and "splitters". Arch Neurol. 2007; 64(6):903-5. DOI: 10.1001/archneur.64.6.903. View

Jarius S, Wildemann B . AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol. 2010; 6(7):383-92. DOI: 10.1038/nrneurol.2010.72. View

Tani T, Sakimura K, Tsujita M, Nakada T, Tanaka M, Nishizawa M . Identification of binding sites for anti-aquaporin 4 antibodies in patients with neuromyelitis optica. J Neuroimmunol. 2009; 211(1-2):110-3. DOI: 10.1016/j.jneuroim.2009.04.001. View

10.

Kinoshita M, Nakatsuji Y, Kimura T, Moriya M, Takata K, Okuno T . Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells. Biochem Biophys Res Commun. 2010; 394(1):205-10. DOI: 10.1016/j.bbrc.2010.02.157. View

11.

Cayrol R, Saikali P, Vincent T . Effector functions of antiaquaporin-4 autoantibodies in neuromyelitis optica. Ann N Y Acad Sci. 2009; 1173:478-86. DOI: 10.1111/j.1749-6632.2009.04871.x. View

12.

McKeon A, Fryer J, Apiwattanakul M, Lennon V, Hinson S, Kryzer T . Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. Arch Neurol. 2009; 66(9):1134-8. DOI: 10.1001/archneurol.2009.178. View

13.

Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M . Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain. 2007; 130(Pt 5):1235-43. DOI: 10.1093/brain/awm062. View

14.

Swanborg R . Experimental autoimmune encephalomyelitis in the rat: lessons in T-cell immunology and autoreactivity. Immunol Rev. 2002; 184:129-35. DOI: 10.1034/j.1600-065x.2001.1840112.x. View

15.

Lucchinetti C, Mandler R, McGavern D, Bruck W, Gleich G, Ransohoff R . A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain. 2002; 125(Pt 7):1450-61. PMC: 5444467. DOI: 10.1093/brain/awf151. View

16.

Bradl M, Misu T, Takahashi T, Watanabe M, Mader S, Reindl M . Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol. 2009; 66(5):630-43. DOI: 10.1002/ana.21837. View

17.

Lapointe B, Herx L, Gill V, Metz L, Kubes P . IVIg therapy in brain inflammation: etiology-dependent differential effects on leucocyte recruitment. Brain. 2004; 127(Pt 12):2649-56. DOI: 10.1093/brain/awh297. View